Synthetic Biology Insights

David, Chamath, and Jason discuss Zymergen's recent stock plummet due to product pipeline issues, CEO change, and revenue projections. They delve into the promise of synthetic biology companies like Zymergen in creating materials, food, and industrial products through cell editing and DNA manipulation.